Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
November 05 2021 - 6:30AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading
clinical-stage genome editing company focused on developing
curative therapeutics using CRISPR/Cas9 technology both in
vivo and ex vivo, today announced the presentation of
data from its ex vivo research and development efforts in two
poster presentations at the 63rd American Society of Hematology
(ASH) Annual Meeting and Exposition, taking place in Atlanta, GA
and virtually from December 11-14, 2021.
“As we continue to advance our full-spectrum strategy, we look
forward to sharing preclinical data from our ex vivo platform with
the research community at this year’s ASH Annual Meeting,” said
Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. “The
data will feature our novel allogeneic technology designed to
overcome rejection by host T and NK cells without the need for host
immune suppression, as well as highlight our clinical-scale
manufacturing process developed for NTLA-5001, our TCR-based T cell
therapeutic candidate for the treatment of acute myeloid leukemia.
Together, the data support our progress toward developing
engineered cell therapies with the potential to transform the lives
of people living with life-threatening diseases.”
ASH Annual Meeting Poster Presentations
Title: A Novel Strategy for Off-the-shelf T
Cell Therapies Evading Host T Cell and NK Cell
RejectionAbstract number:
1711Date/Time: Saturday, December 11, 2021, 5:30
p.m. – 7:30 p.m. ETLocation: Georgia World
Congress Center, Hall B5Presenting
Author: Yong Zhang, Ph.D., associate
director, Cell Therapy
Title: Clinical-scale Production and
Characterization of NTLA-5001 – a Novel Approach to Manufacturing
CRISPR/Cas9Abstract number:
3881Date/Time: Monday, December 13, 2021, 6:00
p.m. – 8:00 p.m. ETLocation: Georgia World
Congress Center, Hall B5
Presenting Author: Daniel Cosette, senior
scientist, Process Development, Engineered T cell Therapies
Additional data collected will be included in final meeting
presentations. All abstracts for the ASH Annual Meeting will be
available on ASH’s website here.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
using CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use intravenously
administered CRISPR as the therapy, in which proprietary delivery
technology enables highly precise editing of disease-causing genes
directly within specific target tissues. Intellia’s ex vivo
programs use CRISPR to create the therapy by using engineered human
cells to treat cancer and autoimmune diseases. Intellia’s deep
scientific, technical and clinical development experience, along
with its robust intellectual property portfolio, have enabled the
company to take a leadership role in harnessing the full potential
of CRISPR/Cas9 to create new classes of genetic medicine. Learn
more at intelliatx.com. Follow us on
Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements”
of Intellia Therapeutics, Inc. (“Intellia” or the
“Company”) within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, express or implied statements regarding
Intellia’s beliefs and expectations regarding its: advancement and
expansion of its CRISPR/Cas9 technology to develop human
therapeutic products, as well as its ability to maintain and expand
its related intellectual property portfolio; expectations of the
potential impact of the coronavirus disease 2019 pandemic on
strategy, future operations and timing of its clinical trials or
IND submissions; and statements regarding the timing of regulatory
filings regarding its development programs.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; and the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies. For
a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is
as of the date of the release, and Intellia undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com Lina
LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.com
mcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024